Drugs / Moxidectin
Moxidectin
also known as
MOX · CL 301,423 · Moxidectin component of advocate · Moxidectin for veterinary use · Moxidectina · Moxidectine · NSC-760424
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MOXIDECTIN | — | 2025-02-07 | fda.gov ↗ |
| Approved | US (FDA) | MOXIDECTIN | — | 2018-06-13 | fda.gov ↗ |
Trials 23 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03962062 | Mar 2021 → May 2022 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 1 | NCT03012828 | Jan → Mar 2017 | — | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 1 | NCT00856362 | Apr → Sep 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00751764 | Nov 2008 → Sep 2009 | infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00736697 | Nov 2008 → May 2009 | infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06070116 | Apr 2024 → Sep 2026 expected | ocular onchocerciasis | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05875441 | Nov 2023 → Nov 2024 | scabies | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 2 | NCT04049851 | Apr 2022 → Jul 2023 | loiasis, ocular onchocerciasis | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | Completed | No outcome recorded |
| Phase 2 | NCT03905265 | Jan 2020 → Feb 2022 | scabies | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 2 | NCT03501251 | Jul → Aug 2018 | trichuriasis | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
| Phase 2 | NCT01035619 | Apr 2011 | onchocerciasis | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00300768 | Sep 2006 → Nov 2009 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04700423 | Mar → Aug 2021 | ascariasis, hookworm infectious disease, intestinal helminthiasis, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 2/3 | NCT04056325 | Nov 2019 → Apr 2021 | strongyloidiasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07159373 | Mar 2026 → Jun 2027 expected | filariasis, scabies, strongyloidiasis | Medicines Development for Global Health | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06188715 | May → Aug 2024 | ascariasis, hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 3 | NCT04848688 | Feb → Jul 2022 | strongyloidiasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 3 | NCT04726969 | Jun → Sep 2021 | ascariasis, hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 3 | NCT03876262 | May 2021 → Jul 2024 overdue | onchocerciasis | Medicines Development for Global Health | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04311671 | May 2021 → Sep 2024 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT00790998 | Apr 2009 → Feb 2012 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07145736 | Aug 2025 → Mar 2029 expected | ascariasis, hookworm infectious disease, onchocerciasis, scabies +1 | Kirby Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06795165 | Feb → Apr 2025 | blepharitis | Eye Research Foundation, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04410406 Comparator | Aug 2020 → Oct 2024 | filariasis | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moxidectin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04049851 ↗23 |
| Known as | CL 301,423 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104415 ↗ |
| Known as | MOX | “Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)” NCT06070116 ↗2“the macrocylic lactone moxidectin (MOX) at 8 mg dosage for onchocerciasis treatment” PMID 38966851 ↗ Apr 2024 “Moxidectin (Mox) 8 mg” NCT04410406 ↗ |
| Known as | Moxidectin component of advocate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104415 ↗ |
| Known as | Moxidectin for veterinary use | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104415 ↗ |
| Known as | Moxidectina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104415 ↗ |
| Known as | Moxidectine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104415 ↗ |
| Known as | NSC-760424 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104415 ↗ |
| Modality | Other / unclassified | “macrocyclic lactone endectocide” NCT03012828 ↗ |
| Route | Oral | “received a single oral dose of 2 mg (N = 44), 4 mg (N = 45) or 8 mg (N = 38) moxidectin or 150 µg/kg ivermectin (N = 45) with 18 months follow up” PMID 24968000 ↗ Jun 2014 |